Nephrology Times

08/06/2025

Desmopressin reduces post-biopsy bleeding and hematoma formation, a study found.

Desmopressin reduces post-biopsy bleeding and hematoma formation, a study found.

08/05/2025

A literature review showed a significant increase in among patients with despite treatment with .

A literature review shed light on hyperkalemia, including a significant increase among patients with chronic kidney disease (CKD) despite treatment with RAASi.

08/05/2025

👀 TAKE A LOOK at the new issue of Nephrology Times, featuring dialysis vs. conservative care, combo therapy for CKD, belimumab for lupus nephritis, felzartamab for IgAN, and more! 👉 https://buff.ly/dVjELGz

08/04/2025

The World Transplant Congress in San Francisco continues! We've started sharing research highlights, with more to come.

Nephrology Times provides highlights from the World Transplant Congress 2025, a significant event in the field of organ transplantation.

08/04/2025

How do SGLT2i and GLP-1RAs affect kidney outcomes in a real-world setting?

Treatment with SGLT2i demonstrated lower rates of chronic kidney disease (CKD) progression to kidney replacement therapy (KRT) compared with GLP-1RAs.

08/03/2025

📬 SUBSCRIBE to our email list to get news and interviews delivered to your inbox.

Sign up for DocWire News eNewsletters to get the latest medical industry news and expert insights and to join an extensive community of health care professionals.

08/02/2025

🎞️ WATCH our latest video interviews.

Read the latest research and news curated for nephrology videos.

08/02/2025

The World Transplant Congress in San Francisco starts TODAY! Keep an eye on nephtimes.com in the coming days for research highlights.

08/01/2025

Higher doses of retatrutide reduced UACR in type 2 diabetes and obesity, but increased eGFR only in obesity, a study showed.

Higher doses of retatrutide reduced urine albumin-to-creatinine ratio in type 2 diabetes and obesity, but increased estimated glomerular filtration rate only in obesity.

07/31/2025

A study demonstrated a link between SARS-CoV-2 infection and greater CKD risks and other kidney outcomes. https://buff.ly/Yikdamf

07/30/2025

⚠️ The FDA has approved pegcetacoplan (Empaveli) for treating C3G and IC-MPGN.

The FDA approved pegcetacoplan for treating C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN in patients age 12 and older.

07/30/2025

Research revealed an association between social isolation and the onset of CVD and accelerated death in CKD.